Australian Clinical Labs (ASX:ACL) said Pinnacle Investment Management Group and its subsidiaries have increased their stake in the company on April 13 to 6.67% or 12.6 million shares from 5.01% or 9.5 million shares, according to a Thursday Australian bourse filing.